Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Learning 2 Sleep represents the Nordic region at HIMSS22 in Helsinki

Learning 2 Sleep

Learning 2 Sleep is one of 13 Nordic health tech companies selected to represent digital health in the Nordic region at the international conference HIMSS22 in Helsinki on 14-16 June.

To showcase the width of companies in digital health and “digital therapeutics - Dtx”, the Nordic cluster organization Health Tech Nordic has selected 13 companies that represent the latest technology in digital health and presents them in a joint stand at the international conference HIMSS22 in Helsinki. The companies present everything from digital triage services to - as in the case of Learning 2 Sleep - concrete treatments for chronic diseases.
“We are proud and happy to have this opportunity and to have been selected. The conference gives us the opportunity to create contacts with major international players such as Cerner, GE-health and ResMed, who have all been perfect partners in our international venture. Thanks to Health Tech Nordic and their joint venture, we are part of a larger context, which of course increases the interest from international players to get in touch, ”says Micael Gustafsson, CEO of Learning 2 Sleep L2S AB (publ).
HIMSS22 is expected to have over 800 visitors from 30+ countries. The congress take place 14-16th of June in Helsinki, Finland.

Contacts


For more information please contact:


Micael Gustafsson, CEO
Mobile: +4673 699 36 01
mail: micael@learningtosleep.se 

About Us


Learning to Sleep is a digital care provider specializing in the treatment of chronic sleep disorders. The treatment is a combination of a structured treatment program in a mobile application and weekly digital meetings with a psychologist. The company's treatment is based on the latest research in the field and is very successful - over 90 percent of the patients treated receive improved sleep. Sweden is the company's main market and the treatment is reimbuserd by public health care.
For more information see www.learningtosleep.co.uk
The company's Certified Adviser is Eminova Fondkomission AB | +468 684 211 10 | adviser@eminova.se

Important information


Publication, publication or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules of the respective jurisdiction. This press release does not constitute an offer of, or invitation to, acquire or subscribe for any securities of L2S in any jurisdiction, either from L2S or from anyone else.

This press release neither identifies nor pretends to identify risks (direct or indirect) that may be attributable to an investment in new shares. An investment decision in connection with the New Issue shall be made on the basis of all publicly available information regarding L2S and L2S's shares. The information in this press release is published only as background information and does not claim to be complete. Thus, an investor should not rely solely on the information contained in this press release or its accuracy or completeness.

This press release does not constitute a recommendation for any investors' decisions regarding the New Issue. Each investor or potential investor should conduct their own research, analysis and evaluation of the business and the information described in this Communication and all publicly available information. The price and value of the securities may decrease as well as increase. Achieved results do not constitute a guide for future results.

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without the application of an exemption from registration, in accordance with the U.S. law in force at any given time. The Securities Act of 1933 ("Securities Act"), and may not be offered or sold in the United States without being registered, exempt from, or in a transaction not covered by the Securities Act registration requirements. There is no intention to register any securities mentioned herein in the United States or to make a public offering in respect of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any other jurisdiction where such publication , publication or distribution of this information would be in violation of applicable rules or where such a measure is subject to legal restrictions or would require additional registration or other measures than those that follow from Swedish law. Measures in violation of these instructions may constitute a breach of applicable securities law.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. L2S has not approved any offer to the public of shares or rights in any Member State of the EEA and no prospectus has been produced or will be produced in connection with the New Issue. In each EEA Member State, this notice is addressed only to "qualified investors" in that Member State as defined in the Prospectus Regulation.

In the United Kingdom, this document, and other material relating to the securities referred to herein, is distributed and directed only to, and an investment or investment activity relating to this document is only available to and will only be used by, "qualified investors" who are ( (i) persons having professional experience in investment activities and falling within the definition of "professional investors" in Article 19 (5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) persons with high net worth referred to in Article 49 (2) (a) - (d) of the Order (all such persons are collectively referred to as "relevant persons"). An investment or investment measure to which this notice relates is only available to relevant persons in the United Kingdom and will only be implemented with relevant persons. Persons who are not relevant persons should not take any action based on this press release, nor should they act or rely on it.

Attachments


Learning 2 Sleep represents the Nordic region at HIMSS22 in Helsinki

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.